Stockscreener 앱 받기
49.67
3.06%
1.475
Veracyte Inc 주식(VCYT)의 최신 뉴스
Veracyte, Inc. Estimates – NASDAQ:VCYT - TradingView
Phase III Trial Shows Veracyte’s Decipher Prostate Test Can Predict Benefit from Adding Abiraterone to Treatment in Very High-Risk Prostate Cancer - The Manila Times
Phase III Trial Shows Veracyte’s Decipher Prostate Test Can Predict Benefit from Adding Abiraterone to Treatment in Very High-Risk Prostate Cancer - GlobeNewswire Inc.
Veracyte: Strong Diagnostic Growth And Improving Margins (NASDAQ:VCYT) - Seeking Alpha
Form 4 Veracyte Inc: Muna Bhanji (Director) For: 19 October By Investing.com - Investing.com South Africa
Veracyte, Inc. (VCYT) Stock Forecasts - Yahoo! Finance Canada
Veracyte, Inc. (VCYT) Stock forecasts - Yahoo Finance UK
Veracyte, Inc. (VCYT) Stock Forecasts - Yahoo Finance
Veracyte Inc (VCYT) Stock Up 3.2% but GF Value Says Overvalued -- GF Score: 80/100 - GuruFocus
Will Veracyte (VCYT) Beat Estimates Again in Its Next Earnings Report? - Zacks Investment Research
Will Veracyte (VCYT) Beat Estimates Again in Its Next Earnings Report? - Yahoo Finance
Veracyte director Muna Bhanji sells $81,456 in company stock By Investing.com - Investing.com Nigeria
How to Boost Your Portfolio with Top Medical Stocks Set to Beat Earnings - Zacks Investment Research
Form 4 Veracyte Inc: Muna Bhanji (Director) For: 19 October By Investing.com - Investing.com Nigeria
Veracyte director Muna Bhanji sells $81,456 in company stock - Investing.com
Director Muna Bhanji Sells 1,864 Shares of Veracyte Inc (VCYT) - GuruFocus
A director sold 1,864 Veracyte (VCYT) shares at $43.70 each under a trading plan. - Stock Titan
Veracyte presents six ESMO studies before results for Veracyte stock - ad-hoc-news.de
Six Studies to Highlight Veracyte’s Genomic Tests Across Breast, Prostate and Bladder Cancer at ESMO 2026 - The Manila Times
Researchers will present first evidence that a prostate test predicts who benefits from an added drug. - Stock Titan
Six Studies to Highlight Veracyte's Genomic Tests Across Breast, Prostate and Bladder Cancer at ESMO 2026 - Moomoo
Veracyte, Inc. (VCYT) Stock Forecasts - Yahoo! Finance Canada
Veracyte, Inc. (VCYT) Stock Forecasts - Yahoo! Finance Canada
Veracyte secures Medicare coverage: 11 analysts rate Veracyte stock - ad-hoc-news.de
A breast cancer test could spare chemotherapy for more than two-thirds of clinically high-risk patients - Stock Titan
Veracyte, Inc. (VCYT) Stock Forecasts - Yahoo Finance
Veracyte Inc. Q3FY26 Results: Release date set for November 4 - scanx.trade
Veracyte, Inc. (VCYT) Stock forecasts - Yahoo Finance UK
Veeva Systems' Basics Gains Traction With 175+ Emerging Biotech Firms - Zacks Investment Research
Veracyte (NASDAQ:VCYT): Affordable Growth Backed by Strong Fundamentals - ChartMill
Veracyte, Inc. (VCYT) Stock Forecasts - Yahoo! Finance Canada
Veracyte, Inc. (VCYT) Stock Forecasts - Yahoo! Finance Canada
Is Veracyte Inc (VCYT) Overvalued After 3.7% Rally? GF Value Say - GuruFocus
Veracyte Inc. (VCYT) Key Financial Ratios – Valuation, Profitability & More - Value Research
ANGO Q1 Earnings Beat Estimates on Med Tech Growth, Revenues Up Y/Y - Zacks Investment Research
Reasons to Hold Veeva Systems Stock in Your Portfolio for Now - Zacks Investment Research
Veracyte, Inc. (VCYT) Stock Forecasts - Yahoo Finance
Is it the Right Time to Add Phibro Stock to Your Portfolio? - Zacks Investment Research
Smith+Nephew Launches CARTIHEAL Implant Across Key European Markets - Zacks Investment Research
Bruker Gains 66.3% in a Year: What's Driving the Rally? - Zacks Investment Research
Reasons to Hold HealthEquity Stock in Your Portfolio for Now - Zacks Investment Research
Veeva's DQS Scales Data Automation Across 1,000+ Clinical Studies - Zacks Investment Research
Reasons to Add Globus Medical Stock to Your Portfolio Now - Zacks Investment Research
Charles River Gains 75.8% in a Year: What's Driving the Rally? - Zacks Investment Research
Is This the Right Time to Add TMO Stock to Your Portfolio? - Zacks Investment Research
Cathie Wood’s ARK sells Teradyne stock, buys Veracyte - Investing.com
Veracyte Inc (VCYT) Shares Fall 6.3% -- What GF Score of 79 Tells Investors - GuruFocus
Cathie Wood's $22M Biotech Shuffle, Dumps One Stock for 21st Straight Session While Other Bets Pile Up - TradingView
Veracyte stock falls 4.64 percent as Decipher data draw focus - AD HOC NEWS
Is It Prudent to Add Teleflex Stock to Your Portfolio Now? - Zacks Investment Research
2.86%
자본화:
|
볼륨(24시간):